Optinose Targets Broad Market with FDA-Approved Sinusitis Treatment XHANCE - MyChesCo
YARDLEY, PA — Pharmaceutical company Optinose has outlined an ambitious commercial strategy following the FDA’s recent approval of XHANCE (fluticasone propionate) for a new indication in treating chronic rhinosinusitis without …
Timothy Alexander
